1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 14 DECEMBER 2015

CNS Drug News 14 DECEMBER 2015

  • December 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - 2015 Trends In Alzheimer's Disease
Industry Trend Analysis - Product Switching Strategy Fails But Cannot Be Ruled Out
Industry Brief - Amarantus Reports Positive Data For Eltoprazine In Alzheimer's Aggression
Industry Trend Analysis - Success In First Phase III Trial Critical For Pharanext's Long-Term Prospects
Industry Brief - AB Science Completes Enrolment In Masitinib Phase III Study In ALS
Industry Brief - Raptor's RP103 36-Month Phase II/III Data Show Promise In HD
Industry Brief - Jubilant Gains Paroxetine ANDA Approval
Industry Brief - Otsuka Seeks Japanese Approval For Additional Indication Of Abilify
Industry Trend Analysis - Phase II Schizophrenia Trial Will Open New Research Avenues
Industry Brief - Trevena's Oliceridine Gains FDA Fast Track Designation For Acute Pain
Industry Brief - Fresenius Kabi Launches Dexmedetomidine
Industry Brief - Orexo Earns European Abstral Milestone Payment; Records OX-MPI Impairment Charge
Industry Brief - Amneal Launches Lidocaine Ointment
Industry Brief - Braeburn/Camurus Initiate Phase III Trial Of Long-Acting Buprenorphine
Industry Brief - Sunovion Reports Positive Health Outcomes Results For Aptiom
Industry Brief - Health Canada Approves Fycompa As Adjunctive Treatment For PGTC Seizures
Industry Brief - Fycompa Launched In Russia For PGTC Seizures
Industry Brief - Zebinix As MT Meets Primary Endpoint In Phase III POS Study
Industry Brief - Swissmedic Approves Akynzeo For CINV
Industry Brief - CNS Conferences - March 2016

Table Of Contents

CNS Drug News 14 DECEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by GlobalData

Schizophrenia - 5EU Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.